Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its pipeline may one day add another $12 billion in sales each year.

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

A legal challenge in Britain to try to ban sales of parts for Lockheed Martin F-35 jets that may end up in Israeli fighters ...

Quest Resource’s first quarter was met with a negative market reaction, following results that fell short of Wall Street ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Capcom stock soared 255% in five years, driven by blockbuster releases and stellar financials, but growth is now decelerating ...

Britain's Volex jumped over 20% on Thursday after the power and data transmission products maker reported double-digit growth in annual revenue and profit, buoyed by strong EV demand and higher North ...

New York’s legal marijuana habit is getting bigger, to the tune of $1.7 billion in sales to date since the regulated market ...

India’s rail tech sector is on track for a historic transformation — from signaling to safety systems. Discover 5 companies ...

Pfizer PFE has committed significant resources for the development of treatments in the fields of oncology, internal medicine ...

India's real estate revival has gained momentum, with large developers experiencing strong pre-sales, rising cash flows, and ...